Home
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
Company Overview
Corporate Strategy
Management Team
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
中国 — 简体中文
Global — English
Home
Technology Platforms
BACK
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
BACK
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
BACK
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
BACK
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
BACK
About Us
Company Overview
Corporate Strategy
Management Team
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
BACK
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
Newsroom
Strive to Deliver Breakthroughs
Press Release
2025
Please select
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
month
Please select
01
02
03
04
05
06
07
08
09
10
11
12
2025-12-29
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
2025-12-17
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
2025-11-24
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
2025-11-07
Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
2025-10-28
Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
2025-10-23
Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
2025-08-27
Harbour BioMed Reports 2025 Interim Results
2025-07-29
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
2025-07-27
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
2025-07-23
HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
1
2
···
3
Jump